Immunomodulating drugs for chronic lymphocytic leukaemia (Q36496055)

14 August 2017

1 reference

title

Immunomodulating drugs for chronic lymphocytic leukaemia (English)

1 reference

14 August 2017

0 references

1 reference

Asher Chanan-Khan

1

1 reference

PubMed ID

16750498

14 August 2017

Carl W Porter

series ordinal

2

1 reference

14 August 2017

1 June 2006

1 reference

Lancet Oncology Commission

14 August 2017

1 reference

14 August 2017

7

1 reference

14 August 2017

480-488

1 reference

14 August 2017

6

1 reference

Determining the Clinical Course and Outcome in Chronic Lymphocytic Leukemia

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Cytokines and intracellular signals involved in the regulation of B-CLL proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Advancing Therapy For Chronic Lymphocytic Leukemia-the Role Of Rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

The emerging role of alemtuzumab in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

The evolving role of alemtuzumab in management of patients with CLL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

B-cell chronic lymphocytic leukemia: a bird of a different feather

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

The angiogenic status of B-CLL B cells: role of the VEGF receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

The levels of TNF alpha, IL4 and IL10 production by T-cells in B-cell chronic lymphocytic leukaemia (B-CLL)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Thalidomide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappaB activation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Thalidomide and immunomodulatory drugs as cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Intratumoral production of IL-6 in B cell chronic lymphocytic leukemia and B lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Thalidomide analogs as emerging anti-cancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970723-9

7 January 2021

10.1016/S1470-2045(06)70723-9

Identifiers

DOI

1 reference

release_grgd66h7zrhcjftceixxshui2q

14 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/grgd66h7zrhcjftceixxshui2q

24 November 2022

mapped directly with Wikidata item

PubMed ID

16750498

1 reference

PubMed ID

16750498